| Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ... New England Journal of Medicine 366 (26), 2455-2465, 2012 | 8837 | 2012 |
| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 6037 | 2015 |
| Treatment of metastatic melanoma: an overview S Bhatia, SS Tykodi, JA Thompson Oncology (Williston Park, NY) 23 (6), 488, 2009 | 789 | 2009 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 723 | 2019 |
| Alterations of immune response of non-small cell lung cancer with azacytidine J Wrangle, W Wang, A Koch, H Easwaran, HP Mohammad, F Vendetti, ... Oncotarget 4 (11), 2067, 2013 | 408 | 2013 |
| Toward eliminating HLA class I expression to generate universal cells from allogeneic donors H Torikai, A Reik, F Soldner, EH Warren, C Yuen, Y Zhou, DL Crossland, ... Blood, The Journal of the American Society of Hematology 122 (8), 1341-1349, 2013 | 353 | 2013 |
| Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial RJ Motzer, B Escudier, S George, HJ Hammers, S Srinivas, SS Tykodi, ... Cancer 126 (18), 4156-4167, 2020 | 254 | 2020 |
| CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma B Escudier, P Sharma, DF McDermott, S George, HJ Hammers, S Srinivas, ... European urology 72 (6), 962-971, 2017 | 252 | 2017 |
| An antigen produced by splicing of noncontiguous peptides in the reverse order EH Warren, NJ Vigneron, MA Gavin, PG Coulie, V Stroobant, A Dalet, ... Science 313 (5792), 1444-1447, 2006 | 246 | 2006 |
| Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a … RJ Motzer, B Escudier, DF McDermott, OA Frontera, B Melichar, T Powles, ... Journal for immunotherapy of cancer 8 (2), 2020 | 203 | 2020 |
| Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma NM Tannir, S Signoretti, TK Choueiri, DF McDermott, RJ Motzer, A Flaifel, ... Clinical Cancer Research 27 (1), 78-86, 2021 | 195 | 2021 |
| Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02) A Diab, NM Tannir, SE Bentebibel, P Hwu, V Papadimitrakopoulou, ... Cancer discovery 10 (8), 1158-1173, 2020 | 193 | 2020 |
| Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial S George, RJ Motzer, HJ Hammers, BG Redman, TM Kuzel, SS Tykodi, ... JAMA oncology 2 (9), 1179-1186, 2016 | 189 | 2016 |
| Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer GV Long, SS Tykodi, JG Schneider, C Garbe, G Gravis, M Rashford, ... Annals of Oncology 29 (11), 2208-2213, 2018 | 179 | 2018 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 172 | 2022 |
| Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition EI Buchbinder, JP Dutcher, GA Daniels, BD Curti, SP Patel, SG Holtan, ... Journal for immunotherapy of cancer 7, 1-7, 2019 | 154 | 2019 |
| Partial activation of CD8+ T cells by a self-derived peptide W Cao, SS Tykodi, MT Esser, VL Braciale, TJ Braciale Nature 378 (6554), 295-298, 1995 | 120 | 1995 |
| Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response … SS Tykodi, EH Warren, JA Thompson, SR Riddell, RW Childs, BE Otterud, ... Clinical cancer research 10 (23), 7799-7811, 2004 | 111 | 2004 |
| Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma DF McDermott, JL Lee, GA Bjarnason, JMG Larkin, RA Gafanov, ... Journal of Clinical Oncology 39 (9), 1020-1028, 2021 | 107 | 2021 |
| Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function JR Veatch, SM Lee, C Shasha, N Singhi, JL Szeto, AS Moshiri, TS Kim, ... Cancer Cell 40 (4), 393-409. e9, 2022 | 79 | 2022 |
